Outset Medical, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $80.8M
- Price
- $4.30
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.87%
- Volume
- 108.9K
About
Outset Medical, Inc. is a medical technology firm that specializes in developing hemodialysis systems. The company's primary product is the Tablo Hemodialysis System, a compact console designed to deliver dialysis treatment in various environments, including hospitals and patients' homes. This innovative system boasts integrated water purification, on-demand production of dialysate, and advanced software complete with connectivity features. Founded in 2003, the company initially operated under the name Home Dialysis Plus, Ltd. before rebranding to Outset Medical, Inc. in January 2015. Its corporate headquarters are located in San Jose, California.
Quick stats
Shares outstanding18.8M
Computed float17.9M
Float / shares95.2%
Key info
SectorHealthcare
IndustryMedical - Devices
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001484612
AI Summary
AI-generated1/32
standardmixedearnings
Outset Medical Reports Second Quarter 2026 Results
Outset Medical reported Q2 revenue of $31.6 million, up 1% year-over-year and 14% sequentially, with gross margin expanding 400 basis points to 42%.
Recurring revenue from consumables and services was $22.1 million, while the company posted a net loss of $18.0 million and maintained a cash position of $151 million.
The company signed a three-year, $40 million refresh agreement with HCA Healthcare and reiterated full-year revenue guidance of $125 million to $130 million.
Red flags
- YoY revenue growth stalled at 1%
- Company remains unprofitable with $9.5 million in net cash used during the quarter